Findings by condition

GLP-1 medicines are studied in many conditions. Each condition is analyzed separately, because a medicine can work differently in people with diabetes than in people with heart failure or liver disease. Choose a condition to see every outcome analyzed for it.

• P01

  Type 2 diabetes (adults)

  380 trials, 220,569 participants

  235 network meta-analyses12 pairwise366 descriptive
• P02

  Overweight or obesity without diabetes (adults)

  95 trials, 52,086 participants

  65 network meta-analyses9 pairwise96 descriptive
• P99

  Other conditions

  63 trials, 7,898 participants
• P09

  Metabolic dysfunction associated steatotic liver disease or steatohepatitis

  18 trials, 2,966 participants

  16 network meta-analyses2 pairwise20 descriptive
• P08A

  Chronic kidney disease with diabetes

  16 trials, 6,134 participants

  12 network meta-analyses53 descriptive
• P12

  Polycystic ovary syndrome

  16 trials, 1,090 participants

  12 network meta-analyses1 pairwise28 descriptive
• P05

  Type 1 diabetes

  14 trials, 2,732 participants

  10 network meta-analyses4 pairwise22 descriptive
• P03

  Children and adolescents with obesity

  7 trials, 702 participants

  14 network meta-analyses2 pairwise12 descriptive
• P04

  Children and adolescents with type 2 diabetes

  6 trials, 569 participants

  9 network meta-analyses30 descriptive
• P02W

  Weight maintenance after a GLP-1 receptor agonist containing run in

  5 trials, 5,700 participants

  8 network meta-analyses16 descriptive
• P07A

  Heart failure with left ventricular ejection fraction above 40 percent

  4 trials, 2,236 participants

  16 descriptive
• P07B

  Heart failure with LVEF 40 percent or lower

  4 trials, 931 participants

  2 descriptive
• P10

  Obstructive sleep apnea

  4 trials, 948 participants

  18 descriptive
• P15

  Antipsychotic associated weight gain and severe mental illness

  4 trials, 258 participants

  2 descriptive
• P11

  Knee osteoarthritis

  2 trials, 336 participants

  4 descriptive
• P13A

  Alzheimer disease

  2 trials, 242 participants

  2 descriptive
• P13B

  Parkinson disease

  2 trials, 257 participants

  14 descriptive
• P14A

  Alcohol use disorder

  2 trials, 175 participants

  6 network meta-analyses8 descriptive
• P14B

  Tobacco use

  2 trials, 279 participants

  14 descriptive
• P06

  Prediabetes or impaired glucose regulation

  1 trials, 267 participants

  2 descriptive